Pharma Marketletter articles from May 2004

Pharma Marketletter archives from May 2004

AstraZeneca forecasts good growth in Spain.(Brief Article)
May 3, 2004... Anglo-Swedish drug major AstraZeneca expects to post double-digit sales growth in Spain this year, buoyed by strong turnover for its respiratory and schizophrenia drugs pipeline, a spokesman for the company in Madrid has told the Marketletter....

Spain's Provitas sees 2003 14% profits hike.
May 3, 2004... Spanish blood-plasma company Probitas Pharma has reported a 14% increase in 2003 net profit to 21.5 million euros ($25.8 million), boosted by strong US and domestic sales of its hemoderivatives products. Moreover, the company, owned by the...

Bayer Spanish unit profits soar 275%.
May 3, 2004... Bayer's operations in Spain have delivered a 275% jump in profits for 2003, after the German pharmaceuticals major sold some properties in Catalonia and benefited from rising drug sales. Bayer rang up net profits of 40 million euros ($48.1...

Norwegian imports up.(medicines and pharmaceuticals )(Brief Article)
May 3, 2004... Norway imported medicines and pharmaceuticals worth 2.03 billion kroner ($293 million) in first-quarter 2004, a year-on-year rise of 3.9%, reports Statistics Norway. Also, Norway's consumer price of health care in March was up 0.1% on...

Finnish pharma trade hit by imports.(Brief Article)
May 3, 2004... Imports of cut-price medications into Finland by private individuals is hurting sales at drug stores in the country, says an article carried in the Nordic Business Report, noting that customs officers at Vantaa airport, Helsinki, reportedly...

GSK ARVs placed on EU anti-diversion list.(GlaxoSmithKline AB)
May 3, 2004... The European Commission has placed seven antiretroviral drugs manufactured by GlaxoSmithKline on the list of medicines protected by the European Union against trade diversion (Marketletters passim). An application for the drugs' listing was...

MedImmune and Cerus sign vaccine deal.(Cerus Corp.)(Brief Article)
May 3, 2004... US firms MedImmune and Cerus Corp have entered into a collaboration to develop and commercialize a therapeutic vaccine for the treatment of cancers of the breast, prostate and colon, as well as metastatic melanomas. "Cerus Corporation's...

Dual Ezetrol/Zocor therapy effective.(Merck and Company Inc.)(Brief Article)
May 3, 2004... Results presented at the European Atherosclerosis Society conference in Seville, Spain, confirm that patients taking Merck & Co/Schering Plough's Ezetrol (Zetia; ezetimibe) in combination with Zocor (simvastatin) have significantly greater...

Genaera to start Ph III AMD trial early 2005.(Brief Article)
May 3, 2004... USA-based Genaera says the US Food and Drug Administration has approved its Investigational New Drug application for its anti-angiogenic drug, squalamine. The IND covers treatment of neovascular diseases of the eye, including wet age-related...

Novartis' Sandostatin LAR OKed in Japan.(Brief Article)
May 3, 2004... The Japanese Ministry of Health, Labor and Welfare has approved the use of Swiss drug major Novartis' Sandostatin LAR (octreotide acetate for injectable suspension) for the treatment of acromegaly and pituitary gigantism which is unresponsive...

Interim data from clofarabine AML trial.(Bioenvision)(Brief Article)
May 3, 2004... Bioenvision of the USA has reported preliminary Phase II data from a European Phase II trial investigating its clofarabine as a first-line therapy in adults with acute myeloid leukemia. These findings were presented at the British Society of...

Neose and BioGeneriX to develop G-CSF.(Neose Technologies Inc.)(GlycoPEGylation technology)(Brief Article)
May 3, 2004... Neose Technologies of the USA and Germany's BioGeneriX have signed an agreement to utilize the former's proprietary GlycoPEGylation technology to develop a long-acting, next-generation version of granulocyte colony stimulating factor. G-CSF is...

FDA accepts rolling NDA for Dacogen.(New Drug Application)(Brief Article)
May 3, 2004... SuperGen says the US Food and Drug Administration has granted its request for a rolling New Drug Application filing for Dacogen (decitabine) for injection. The submission will focus on gaining authorization for use of the product in patients...

Pharma's "corporate citizenship" deserves greater recognition, says AFM director.(Africa Fighting Malaria)
May 3, 2004... Media obsession with depicting the pharmaceutical industry in a bad light obscures the enormous amount of good done in "corporate citizenship projects," a South African economist complained this week. Richard Tren, the executive director of the...

Red tape stiffling Taiwan's pharma and biotech industries, say local firms.
May 3, 2004... Taiwan's government must cut the red tape which is stifling development of the domestic biotechnology sector according to Chen Kuang-chi, chief executive of local firm Maywufa Bio-Pharmaceutical, who said in an interview that "Taiwan's...

Drug price, shortages foreseen in India.(Brief Article)
May 3, 2004... Prices of drugs, including those which are off patent, may see a significant hike and even the availability of some medicines may become a critical problem in India once the country switches to a product patent system from January 1, 2005. This...

PAREXEL acquires balance of 3ClinicalResearch for $12M.(3ClinicalResearch AG)(PAREXEL International Corp.)(Brief Article)
May 3, 2004... US firm PAREXEL International has acquired 3ClinicalResearch AG, a clinical research organization with expertise in Phase I and Phase IIa proof-of-concept studies. The privately-held company is based in Berlin, Germany, and has Phase I/IIa...

AngioGenex and BioCheck in cancer testing deal.(Brief Article)
May 3, 2004... US firms AngioGenex and BioCheck have entered into an agreement to develop cancer diagnostic and prognostic products based on the Id-gene platform technology licensed exclusively to AGx by the Albert Einstein College of Medicine and the...

Spectrum completes $26M placing.(Spectrum Pharmaceuticals Inc.)(Brief Article)
May 3, 2004... Spectrum Pharmaceuticals of the USA has raised approximately $25 million through a private placement of around 3.2 million shares of its common stock to select institutional and other investors at a price of $7.75 per share. In addition,...

Serono "Lifeline" for people with fertility concerns.(Brief Article)
May 3, 2004... Serono Inc, the US subsidiary of the like named Swiss biotechnology firm and a leader in reproductive health, has announced a series of national teleconferences to mark the launch of Fertility LifeLines, a free educational service that offers...

Battle for Polfa Kutno hots up.(Polfa Kutno)(Brief Article)
May 3, 2004... Following the announcements during April of takeover bids for Polish drugmaker Polfa Kutno, first from Italy's Recordati and then from US generics firm IVAX Corp (Marketletters April 12 and 19), the battle for the company has hotted0 up with...

Merck & Co reports 5% drop in 1st-qtr income.
May 3, 2004... US drug major Merck & Co saw its first-quarter 2004 net income drop 5% to $1.62 billion, or $0.73 per share, compared to the year-earlier period which included financials from the firm's recently-divested pharmacy benefits business, Medco...

Wyeth posts 9% rise in 1st-qtr revenue.(a potentially damaging lawsuit related to a fen-phen death may prove financially damaging to Wyeth)
May 3, 2004... US drugmaker Wyeth recorded net revenues of $4.0 billion for the first quarter of 2004, rising 9% from the comparable period of last year. Reported net income and diluted earnings per share for the quarter were $749.7 million and $0.56,...

S-P posts 1st-qtr loss of $73M as sales slide.
May 3, 2004... The USA's Schering-Plough has recorded a loss for the first quarter of 2004 of $73 million, or $0.05 per share, down from earnings of $173 million, or $0.12 per share, for the like, year-earlier period. The loss for the quarter absorbed...

Baxter's sales climb 11% for 1st-qtr 2004.(Brief Article)
May 3, 2004... Baxter International of the USA saw its sales rise 11% to $2.21 billion for the first quarter of 2004 from the comparable period last year, including a 7% boost from currency exchange effects. Income from continuing operations totaled $189...

Forest posts 20% jump in fiscal-2003 sales.(Brief Article)
May 3, 2004... New York, USA-headquartered Forest Laboratories has achieved a 20% rise in sales to $2.65 billion for the fiscal year ending March 31, 2004. Net income increased 18% to $736 million from $622 million. The results were driven by a strong...

Pharma urged: "comment on MMA changes to Waxman-Hatch before rulemaking".(Medicare Modernization Act)
May 3, 2004... Elizabeth Dickson, associate counsel for drugs in the Office of the General Counsel at the US Food and Drug Administration, has called on the pharmaceutical industry to comment on changes incorporated into the Medicare Modernization Act before...

US multi-state drug-buying pool approved.(Brief Article)
May 3, 2004... The US government has formally approved the Medicaid drug-buying pool set up in 2003, ahead of approval, by Michigan and Vermont states (Marketletters passim). The pool's other members are Alaska, New Hampshire and Nevada; Hawaii is...

Antisoma/Roche's R1549 fails in Ph III.(Roche Holding Ltd.)(clinical trials)(Brief Article)
May 3, 2004... Swiss drug major Roche and UK-based Antisoma say that drug candidate R1549 did not meet its primary endpoint in a Phase III trial in ovarian cancer. In SMART (Study of Monoclonal Antibody RadioimmunoTherapy), the outcomes for R1549-treated...

Wilex and Esteve sign deal for Rencarex.(Laboratorios Esteve )(Brief Article)
May 3, 2004... Germany-based Wilex AG and Laboratorios Esteve of Spain have signed a co-development and marketing agreement for the former's chimeric antibody Rencarex (WX-G250) in southern Europe. The agent is under evaluation as a treatment for renal cell...

GSK's Advair OKed for use in children by FDA.(GlaxoSmithKline AB)(Brief Article)
May 3, 2004... The US Food and Drug Administration has approved the use of UK drug major GlaxoSmithKline's Advair Diskus in children four to 11 years of age with asthma who are symptomatic on inhaled corticosteroid therapy alone. The product is a combination...

Positive Ph III findings for Tarceva in NSCLC.(National Cancer Institute of Canada Clinical Trials Group )(Brief Article)
May 3, 2004... USA-based Genentech and OSI Pharmaceuticals and Switzerland's Roche have released promising data from a Phase III study of Tarceva (erlotinib) in relapsed non-small cell lung cancer patients. The study was conducted by OSI in conjunction...

Early therapy with rasagiline beneficial.(Brief Article)
May 3, 2004... Findings published in the April issue of Archives of Neurology show that Parkinson's disease patients taking Teva's rasagiline for 12 months exhibit less impairment than those subjects whose treatment was delayed for six months. The...

French govt pressure and increased offer push Aventis into marriage with Sanofi.(Sanofi Synthelabo)
May 3, 2004... Under intense pressure from the French government, France-headquartered drugmakers Aventis and Sanofi-Synthelabo have reached agreement on a merger, which the former previously rejected (Marketletters passim). Aventis' management is...

KV Pharma prevails in CIMA/Schwarz DuraSolv patent case.(KV Pharmaceutical Co.)(CIMA LABS Inc.)(Schwarz Pharma)(Brief Article)
May 3, 2004... St Louis, USA-based KV Pharmaceutical says that the US District Court for the District of Minnesota has denied a motion for a preliminary injunction filed by CIMA Labs and Schwarz Pharma, in a patent infringement action brought against KV and...

ISTA Pharma files $75M shelf registration statement.(Ista Pharmaceuticals Inc. securities)(Brief Article)
May 3, 2004... ISTA Pharmaceuticals of the USA says that it has filed a universal shelf registration statement on Form S-3 with the US Securities and Exchange Commission, providing for the offering from time to time of up to $75 million of its securities,...

Pfizer sells diagnostics unit.(Brief Article)
May 3, 2004... World-leading pharmaceutical company Pfizer has completed the sale, announced January 19, of its in vitro allergy and autoimmune diagnostic testing business to Triton, an independent European private equity firm, and PPM Ventures, the private...

Bayer Healthcare realigns diagnostics division.(Bayer HealthCare Diagnostics Self-Testing Systems Division)(Bayer HealthCare Diagnostics Professional Testing Systems Division)(Brief Article)
May 3, 2004... The Diagnostics Division of Germany's Bayer is to be be divided into two entities - Bayer HealthCare Diagnostics Self-Testing Systems Division (STS) and Bayer HealthCare Diagnostics Professional Testing Systems Division (PTS), effective June 1....

Inyx acquires brands to expand in UK hospitals.(Brief Article)
May 3, 2004... US firm Inyx Inc, an emerging specialty pharmaceutical company with a focus on niche drug delivery technologies and products, has acquired a group of parenteral pharmaceutical product licenses that will enable the company to enter the hospital...

India's Ranbaxy, Wockhardt, NPIL and Sun Pharma post good quarterly results.(Nicholas Piramal India Ltd.)(Ranbaxy Laboratories Ltd.)
May 3, 2004... India's four major pharmaceutical companies, buoyed by good domestic and foreign demand, have announced excellent to good latest quarterly profits. Company officials predict that demand and profits are likely to be sustained in the current...

Efroze launches drugs in Nigeria.(Efroze Chemical Industries)(Brief Article)
May 3, 2004... Efroze Chemical Industries, a leading Pakistani drugmaker, has introduced a range of its products to the Nigerian market to compete with existing brands in the country. Speaking at a joint press conference in the Nigerian capital of Lagos,...

Schering AG's 1st-qtr beats expectations.(Brief Article)
May 3, 2004... German drugmaker Schering AG has posted strong first-quarter 2004 results, which were ahead of consensus forecasts, with total sales of 1.17 billion euros ($1.40 billion) and earnings per share of 0.67 euros, despite pricing pressure in...

Managed care backs Rx comparative effectiveness studies.(Brief Article)
May 3, 2004... The US Academy of Managed Care Pharmacy has announced its support for increased research into the comparative clinical and cost effectiveness of prescription drugs and called on the federal government to assume principal responsibility for...

J&J to offer free drugs to many with CMS-endorsed Rx cards.(Johnson & Johnson)(Centers for Medicare and Medicaid Services)(Brief Article)
May 3, 2004... Johnson & Johnson's US pharmaceutical operating companies will offer their drugs free to low-income Medicare beneficiaries who enroll in many of the new US Centers for Medicare and Medicaid Services-endorsed Medicare prescription drug discount...

South Africa new Rx price regs; final form "impacted by previously-unavailable data".
May 3, 2004... Ahead of their publication in the Government Gazette, South African Health Minister Manto Tshabalala-Msimang has discussed the country's new drug price regulations (Marketletters passim), in order to "end speculation and give stakeholders and...

World Rx sales up 8% in 12 months to February.(Brief Article)
May 3, 2004... Drug sales through retail pharmacies grew 8% overall in 13 key world markets during March 2003-February 2004, closing at $321.07 billion, reports IMS Health. US sales rose 10% to $163.97 billion, while Europe's five leading markets...

French Minister "no" to partial Rx pack charges.(Brief Article)
May 3, 2004... French Health Minister Philippe Douste-Blazy is due to present his new proposals on reform of the health service to the Ministerial Council in mid-June, but he has already rejected a call to apply a partial charge to certain drug products by...

Bringing coherence to EU biotech policies.
May 3, 2004... Progress has been made in the European Union, by biotechnology sector players as well as public and business stakeholders, in implementing the European Commission's Life Sciences and Biotechnology Strategy, says the Commission's second annual...

Russia to centralize pharma supervision.(Brief Article)
May 3, 2004... Russia is to set up, for the first time, a single federal agency to control the quality, licensing and price of medicines, the RIA Novosti news agency reports Russian Health Minister Mikhail Zurabov as stating. The quality of medical...

EMEA views patient info improvements.(Brief Article)
May 3, 2004... The European Medicines Evaluation Agency has published recommendations on improving information for patients. The proposals, which have been drawn up in collaboration with patients' organizations, fall into three main areas: providing...

Spanish Rx prices in March.(pharmaceuticals)(Brief Article)
May 3, 2004... In March, the consumer price of pharmaceuticals in Spain was up 0.1% over February and 2.5% down on March 2003, while the rises in the price of health care were 0.3% and 2.3%, respectively, reports the National Statistics Institute. In...

Actelion sees record revenues for 1st-qtr.(Brief Article)
May 3, 2004... Swiss firm Actelion saw its first-quarter 2004 revenues rise above the 100 million Swiss francs ($76.6 million) mark for the first time, achieving a 61% leap from the comparable period last year to 101.1 million francs. The company posted...

Gilead 1st-qtr 2004 revenues rocket 87%.(Brief Article)
May 3, 2004... USA-based Gilead saw its revenues shoot up 87% to $309 million for the first quarter of 2004, driven by a "superb" performance from its lead drug Viread (tenofovir disoproxil fumarate), the company said. Net income for the quarter reached...

Amgen's EPS for 1st-qtr 2004 jumps 36%.(Brief Article)
May 3, 2004... Amgen, the world's largest biotechnology firm, posted adjusted earnings per share of $0.57 for the first quarter of 2004 versus $0.42 for the like, year-earlier period and representing a substantial increase of 36%. USA-based Amgen...

Bayer/GSK's Levitra takes 3rd place in UK.(Brief Article)
May 3, 2004... According to a report in the Sunday Times, Bayer AG and GlaxoSmithKline's Levitra (vardenafil), for erectile dysfunction, is flagging behind its main competitor, Eli Lilly's Cialis (tadalafil), in the race to beat current global number one,...

Neose and MacroGenics accord on MAbs.(Neose Technologies Inc.)(Brief Article)
May 3, 2004... US firms Neose Technologies and MacroGenics have entered into a research collaboration and license agreement on multiple monoclonal antibodies. Neose will apply its GlycoAdvance and GlycoPEGylation technologies to MacroGenics' compounds, with...

Novartis announces hypertension initiative.(health programs)(Brief Article)
May 3, 2004... In the USA, Novartis has announced what it says is an unprecedented national initiative to help patients and health care professionals take action against high blood pressure. The program offers educational and motivational tools for a...

FTC calls for more info on Genzyme ILEX merger.(Ilex Oncology Inc.)(Federal Trade Commission)(Brief Article)
May 3, 2004... Genzyme Corp says that it has received a request from the US Federal Trade Commission for more information relating to its previously-announced acquisition of ILEX Oncology (Marketletters passim). The companies intend to respond promptly...

aaiPharma completes asset sales, closes $140M credit facility.(Brief Article)
May 3, 2004... aaiPharma of the USA says it has completed the sale of its MVI (multi-vitamin infusion) and Aquasol product business for $105 million to Mayne Pharma (USA) Inc, a subsidiary of Australia's Mayne Group. The total consideration received of $94.2...

Sankyo sues rival for alleged infringement of Mevalotin tech.(Nissin Pharmaceutical)(Sankyo Company Ltd.)(Brief Article)
May 3, 2004... Japanese drug major Sankyo has filed a law suit with the Tokyo District Court alleging that Yamagata Prefecture-based Nissin Pharmaceutical has infringed on its patented technology used to stabilize the quality of its best-selling...

Turkey, an attractive new option for clinical trials?(Brief Article)
May 3, 2004... Countries such as Turkey, which are hoping to join the European Union in the future, are emerging as promising areas for clinical research, says Christine Ott of leading independent contract research organization Chiltern International. ...

Fluoroquinolone use set to increase, says Datamonitor.(Brief Article)
May 3, 2004... A new report from market analyst Datamonitor suggests that increasing evidence of bacterial resistance to older drugs will lead to a greater use of fluoroquinolones, despite warnings of decreasing sensitivities and adverse events. ...

Medarex/UMMS' SARS antibody to be tested in China.(University of Massachusetts)(Brief Article)
May 3, 2004... Medarex says a fully-human antibody to severe acute respiratory syndrome, developed by the US firm in conjunction with the University of Massachusetts Medical School, USA, has been shipped to Beijing, China, for preclinical testing. The...

Latvia: 5%VAT on medicines from May 1.(Brief Article)
May 3, 2004... While pharmaceuticals are currently exempt from value-added tax in Latvia, the country will introduce VAT at a rate of 5% on them on May 1, and this is expected to lead to a 5% rise in the retail price of drugs, reports Baltic Business News....

Latvia: still too many pharmacies for EU.(Brief Article)
May 3, 2004... The number of pharmacies in Latvia fell from 868 in 2001 to 837 in 2003, but analysts in the capital Riga say the country still has too many, prior to its membership of the European Union, reports Baltic Business News. Current national...

WHO urges access to new antimalarials.(World Health Organization)
May 3, 2004... Over 600 million people, mostly children in sub-Saharan Africa, face the daily threat of death from malaria because new, effective treatments are not available to them. Existing, cheaper drugs which have been used for many years are generally...

AstraZeneca bolsters R&D with new facility.(Brief Article)
May 3, 2004... The UK's AstraZeneca has opened a state-of-the-art Automated Compound Management Facility at its Wilmington R&D campus in Delaware, USA.Uunder the firm's four-year, $165 million investment in USA-based research facilities, this latest $13...

Medarex to offer $125M of convertible senior notes.(Brief Article)
May 3, 2004... The USA's Medarex intends to offer $125 million of convertible senior notes, expected to be due in 2011, in a private offering to institutional investors, convertible into Medarex stock at an as yet undetermined price. Net proceeds from...

Cedegim acquires Pharma Marketing.(Brief Article)
May 3, 2004... France-based Cedegim, a provider of solutions for enhancing health care industry sales and marketing resources, has acquired its Norwegian peer Pharma Marketing. Under the terms of the deal, Cedegim acquires Pharma Marketing's entire suite...

GroPep to invest A$3M in facility upgrade.(Brief Article)
May 3, 2004... Biopharmaceutical firm GroPep Ltd intends to invest around A$3 million ($2.19 million) in the expansion and modernization of its manufacturing facilities in Therbarton, Australia, in order to support its rapidly-increasing cell culture products...

New strategies revealed to improve FDA's efficiency, including an alliance with SEC.(Food and Drug Administration)(Securities and Exchange Commission)
May 3, 2004... Speaking at the recent US Food and Drug Law Institute conference (see also page 14 this issue and Marketletter April 26), Jeffrey Reidler, assistant director in the division of corporate finance at the US Securities and Exchange Commission,...

Tokyo pharma stocks - week to April 26.
May 3, 2004... Tokyo saw a rally in the week ended April 26, on resumed active buying principally by domestic institutional investors with new funds for their new fiscal year. The Nikkei 225 went up 3.4% to close at 12,163.89, a new high for this year, while...

Medco settles, agrees more transparency.(Medco Health Solutions Inc.)
May 3, 2004... Medco Health Solutions, the USA's largest pharmacy benefits manager, has agreed to pay $29.3 million to 20 US states and the US Attorney in Philadelphia to settle charges that it violated state trade practice laws by pressing doctors to switch...

DTC ads "prompting fewer patients to act".(direct-to-consumer)(Brief Article)
May 3, 2004... US spending on direct-to-consumer advertising for prescription drugs has regained momentum due to competitive activity heated by recent drug launches (particularly in the erectile dysfunction and elevated cholesterol treatment categories), but...

Maryland AG's Rx price web site launches.(Brief Article)
May 3, 2004... The web site of Attorney General Joseph Curran of the US state of Maryland is now providing price comparisons at 1,200 retail pharmacies for the state's 25 most-prescribed medications. Maryland has also announced that it is formally...

German health reforms "working".(Brief Article)
May 3, 2004... Germany's Health Minister, Ulla Schmidt, and the official representative of German patients, Helga Kuehn-Mengel, say the health service reform is working. Over a third of patients with health insurance have seen their contribution rates...

GSK, WHO-TDR, Medicines for Malaria Venture in ACT accord.(GlaxoSmithKline, World Health Organization-Training in Tropical Diseases, artemisinin combination therapy drug)
May 3, 2004... GlaxoSmithKline, the World Health Organization's Special Programme for Research and Training in Tropical Diseases (WHO-TDR) and the Medicines for Malaria Venture have signed a collaborative agreement to develop a new-fixed dose artemisinin...

Latvian drugs market grew 12.4% in 2003.(Belin Chemie/Menarini and GlaxoSmithKline plan to increase sales to Latvia)(Brief Article)
May 3, 2004... The Pharmaceutical Department of Latvia's Ministry of Health reports that the value of pharmaceuticals production in the country in 2003 was $58.7 million, a rise of 19% on 2002, according to the Baltic Business News. Also last year, the...

Safety of antidepressants in children questioned again; Lancet study.
May 3, 2004... A new study published in the Lancet, reviewing published and unpublished results, suggests that the risks associated with the use of most selective serotonin reuptake inhibitors in children with depression could outweigh their benefits. ...

Millennium/J&J's Velcade gets EU OK.(Johnson & Johnson's)(Brief Article)
May 3, 2004... The European Commission has approved the use of Millennium/Johnson & Johnson's Velcade (bortezomib). The agent is cleared for the treatment of patients with multiple myeloma who have received at least two prior therapies and have demonstrated...

Orphan's net loss climbs for 1st-qtr.(Orphan Medical Inc.)(Brief Article)
May 3, 2004... USA-based Orphan Medical posted a net loss for the first quarter of 2004 of $4.3 million, or $0.40 per share, versus $4.1 million, or $0.39 per share, for the like, year-earlier period. Sales for the quarter were $5.4 million, absorbing $1...

Cytos sees sales rocket 870% for 1st-qtr.(Brief Article)
May 3, 2004... Switzerland's Cytos Biotechnology AG has posted an enormous 870% leap in revenues to 2.7 million Swiss francs ($2.1 million) for the first quarter of 2004. The firm noted that this increase is primarily the result of its collaboration with...

GroPep reports positive cash flow for 1st-qtr.(Brief Article)
May 3, 2004... Australia's GroPep Ltd has achieved positive operating and net cash flow for the fourth consecutive quarter. The company posted cash flow of A$1.0 million ($730,000) for the first quarter of 2004, including positive operating cash flow of $1.5...

B-MS announces paraplatin settlement.(Bristol-Myers Squibb Co.)(Brief Article)
May 3, 2004... Bristol-Myers Squibb has settled a patent litigation case which it initiated with patent holder Research Corporation Technologies against Pharmachemie Group, a subsidiary of Israel's Teva Pharmaceutical Industries, regarding the chemotherapy...